IN8bio, Inc. (NASDAQ:INAB – Free Report) – Equities research analysts at Zacks Small Cap lifted their Q3 2024 EPS estimates for shares of IN8bio in a report issued on Wednesday, August 14th. Zacks Small Cap analyst J. Vandermosten now forecasts that the company will post earnings per share of ($0.14) for the quarter, up from their prior forecast of ($0.15). The consensus estimate for IN8bio’s current full-year earnings is ($0.60) per share. Zacks Small Cap also issued estimates for IN8bio’s FY2024 earnings at ($0.65) EPS and FY2025 earnings at ($0.68) EPS.
IN8bio (NASDAQ:INAB – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03).
Read Our Latest Research Report on INAB
IN8bio Stock Performance
Shares of INAB opened at $0.53 on Monday. The firm has a 50-day moving average of $0.84 and a 200-day moving average of $1.02. IN8bio has a one year low of $0.50 and a one year high of $2.48. The company has a market cap of $23.28 million, a PE ratio of -0.58 and a beta of 0.06. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.10 and a quick ratio of 4.10.
Institutional Trading of IN8bio
An institutional investor recently bought a new position in IN8bio stock. AIGH Capital Management LLC acquired a new position in IN8bio, Inc. (NASDAQ:INAB – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 4,098,361 shares of the company’s stock, valued at approximately $5,216,000. IN8bio makes up approximately 2.1% of AIGH Capital Management LLC’s investment portfolio, making the stock its 20th biggest position. AIGH Capital Management LLC owned 12.81% of IN8bio at the end of the most recent reporting period. Institutional investors and hedge funds own 92.05% of the company’s stock.
IN8bio Company Profile
IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.
Read More
- Five stocks we like better than IN8bio
- Dividend Capture Strategy: What You Need to Know
- Columbia Sportswear: A Turnaround Story That’s Gaining Ground
- What to Know About Investing in Penny Stocks
- Lowe’s Stock: Hold Now, Buy it When it Dips
- How to Use the MarketBeat Dividend Calculator
- ZIM Shipping Stock Soars as the Industry Shows a Bottoming Trend
Receive News & Ratings for IN8bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IN8bio and related companies with MarketBeat.com's FREE daily email newsletter.